SCHEDULE: Jorey Chernett Boosts OKYO Pharma Stake to 7.76%

Jorey Chernett has filed an amendment to Schedule 13G, reporting beneficial ownership of 7.76% of OKYO Pharma Ltd's common stock as of September 30, 2025.

Summary

• Jorey Chernett reported beneficial ownership of 2,984,862 shares of OKYO Pharma Ltd common stock.
• This represents 7.76% of the company's common stock.
• Chernett holds sole voting and sole dispositive power over all these shares.
• The filing is an Amendment No. 1 to Schedule 13G, indicating a change from a previous filing.
• The event date requiring this filing is stated as September 30, 2025, with a signature date of November 13, 2025.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership, which inherently carries a neutral sentiment. The significant stake could be interpreted positively as investor confidence, but the filing itself is purely informational.

Positives

• Jorey Chernett holds a substantial 7.76% stake in OKYO Pharma Ltd, indicating significant investor confidence.
• Chernett maintains sole voting and dispositive power over all 2,984,862 shares, suggesting direct control over this block.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant individual stake (7.76%) by Jorey Chernett may signal confidence in OKYO Pharma Ltd, potentially influencing investor perception.

Key Dates

Keywords

OKYO Pharma Ltd, Jorey Chernett, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investor Stake